Education
About Us
Working with TipRanks
Follow Us
Madrigal (GB:0JXI)
:0JXI
Earnings Data
Report Date
Mar 04, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.66Last Year’s EPS
-2.71Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call reflects a strong quarter for Madrigal Pharmaceuticals, driven by the successful launch of Rezdiffra and robust financial health. However, increased operating expenses and ongoing challenges with payer contracting highlight areas of concern. Additionally, competitive pressures from other entrants in the MASH market could impact future growth. Overall, the sentiment is cautiously optimistic.Company Guidance
Successful Launch of Rezdiffra
Rezdiffra's net sales for the third quarter were $287 million, up 35% quarter-over-quarter, with over 29,500 patients treated and more than 10,000 healthcare providers prescribing the drug.
Patent Extension and Global Expansion
Rezdiffra's U.S. patent is now listed in the orange book, extending its value until 2045. Additionally, the drug has launched in Germany following European approval.
Pipeline Advancements
Progress on the Phase III MAESTRO-NASH outcomes trial for compensated MASH cirrhosis, with new data expected. The company is also advancing a combination strategy with a new oral GLP-1.
Strong Financial Position
Madrigal ended the third quarter with $1.1 billion in cash, cash equivalents, restricted cash, and marketable securities, despite a one-time $117 million R&D expense.
GB:0JXI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0JXI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $409.83 | $455.01 | +11.02% |
Aug 05, 2025 | $307.15 | $340.68 | +10.92% |
May 01, 2025 | $342.66 | $329.39 | -3.87% |
Feb 26, 2025 | $319.08 | $362.01 | +13.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Madrigal (GB:0JXI) report earnings?
Madrigal (GB:0JXI) is schdueled to report earning on Mar 04, 2026, Before Open (Confirmed).
What is Madrigal (GB:0JXI) earnings time?
Madrigal (GB:0JXI) earnings time is at Mar 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Madrigal stock?
The P/E ratio of Madrigal Pharmaceuticals is N/A.
What is GB:0JXI EPS forecast?
GB:0JXI EPS forecast for the fiscal quarter 2025 (Q4) is -0.66.